Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

NicVAX (Nabi Biopharmaceuticals).

Christine E Heading1

  • 1The Open University, Department of Biological Sciences, Walton Hall, Milton Keynes MK7 6AA, UK. moore11@globalnet.co.uk

Idrugs : the Investigational Drugs Journal
|December 11, 2003
PubMed
Summary

Nabi Biopharmaceuticals is developing NicVAX, a novel vaccine for nicotine addiction. This therapeutic vaccine aims to help individuals quit smoking and manage nicotine dependence.

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gender issues and the pharmacotherapy of substance abuse.

IDrugs : the investigational drugs journal·2008
Same author

Drug evaluation: CYT-002-NicQb, a therapeutic vaccine for the treatment of nicotine addiction.

Current opinion in investigational drugs (London, England : 2000)·2007
Same author

Vivitrex (Alkermes/Cephalon).

Current opinion in investigational drugs (London, England : 2000)·2006
Same author

Conus toxins: targets and properties.

IDrugs : the investigational drugs journal·2004
Same author

Recent advances against substance abuse.

IDrugs : the investigational drugs journal·2003
Same author

TA-CD. Xenova.

IDrugs : the investigational drugs journal·2003

Area of Science:

  • Pharmacology
  • Immunology
  • Addiction Medicine

Background:

  • Nicotine addiction remains a significant public health challenge.
  • Existing treatments for nicotine dependence have varying success rates.

Purpose of the Study:

  • To introduce NicVAX, a proprietary vaccine developed by Nabi Biopharmaceuticals.
  • To highlight NicVAX's potential as a therapeutic intervention for nicotine addiction.

Main Methods:

  • NicVAX is a proprietary vaccine.
  • It is designed as a therapeutic agent.

Main Results:

  • The vaccine targets nicotine addiction.
  • It aims to prevent and treat nicotine dependence.

Conclusions:

  • NicVAX represents a novel approach to combating nicotine addiction.
  • Further research and clinical trials are anticipated.